本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
Hsinchu, Taiwan – March 20, 2025, in an era of rapidly evolving wireless connectivity technologies, ACE Solution successfully held the "Leading the Future of Wireless: Smart Collaboration and Integration" seminar, igniting new opportunities for wireless connectivity and smart factory innovation. Industry experts gathered to discuss the integration of WiFi-7 era intelligent factory automation and wireless testing technologies, sparking AI innovation and ushering in a new chapter of the Internet of Everything. With high-speed transmission and interference among various communication signals posing significant challenges, electromagnetic interference (EMI) has increasingly affected transmission quality. To address these challenges, ACE Solution, in collaboration with LitePoint and Universal Robots, shared innovative tools for precise interference source identification and intelligent testing integration solutions, empowering companies to overcome technological bottlenecks. The seminar commenced with opening remarks by ACE Solution Marketing VP Tony Hsu, who provided an in-depth analysis of market trends and emphasized the impact of wireless technology and innovative collaboration on the industry's future. Featured presentations included ACE Solution GM Frank Chang discussing "Intelligent Test Integration Leading the Future of Wireless," LitePoint Sales Vice General Manager Adonis Lee presenting "Unlocking WiFi-7 to Empower a New Era of IoT and Wireless Connectivity," Universal Robots Business Development Manager Alan Lu sharing "Human-Robot Collaboration: Boosting Production Efficiency and Volumes," ACE Solution Technical Manager Max Hung addressing "Overcoming Electromagnetic Interference for Precise Testing: EMI Challenges and Solutions," and ACE Solution Technical Manager Bruce Cheng summarizing with "Launching Smart Strategies: Integrated Testing of Wireless Products." In addition to the insightful presentations, the seminar featured four interactive exhibition areas where attendees could experience cutting-edge technological solutions firsthand. The showcased areas included Wireless Communication Automation Integrated Testing Solution, Smart Factory Collaborative Automation Solution, EMI Electromagnetic Wave Automated Scanning System, and New Approach to Measurement Instruments – Available for Rental or Purchase. Through practical demonstrations and interactive experiences, participants gained valuable insights into the potential and innovation of these technological applications. The successful conclusion of this seminar showcased ACE Solution's technological leadership in wireless communication and intelligent collaboration. It also provided a valuable platform for industry professionals to enhance their understanding of innovative technologies and foster collaboration. Moving forward, ACE Solution will continue to refine its technologies and services, working hand-in-hand with industry partners to create a new chapter in the era of innovative technologies.
(台灣新竹，2025年03月20日)，在無線連接技術飛速發展的時代，筑波科技成功舉辦「引領無線未來 智慧協作整合新格局」研討會，科技共創引爆無線連接與智慧工廠的未來新契機。本次盛會齊聚業界菁英，共同探討WiFi-7時代的智慧工廠自動化與無線測試技術整合，點燃AI創新，開啟萬物互聯的全新篇章！高速傳輸與多種通訊訊號間的相互干擾已成為產業面臨的巨大挑戰，電磁干擾問題對傳輸品質的影響日益嚴重。為了克服這一難題，筑波科技攜手LitePoint與Universal Robots，分享精準定位干擾源的創新工具與智能測試整合方案，助力企業突破技術瓶頸。 本次研討會由筑波科技行銷副總許棟材揭開序幕，深入剖析市場趨勢並強調無線技術與智慧協作對產業未來的影響。演講議程包含筑波科技總經理張佳楙分享「智能測試整合引領無線未來」，LitePoint業務副總李鎮如則以「開啟 WiFi-7 賦能萬物互聯、無線連接的新篇章」為題。隨後，Universal Robots業務發展經理呂亞倫發表「人機協作：助力產線提升效能與產能」，筑波科技技術經理洪子程則分享「突破電磁干擾，實現精準測試：EMI 的挑戰與解決方案」，最後，筑波科技技術經理鄭翔駿以「啟動智能新策略：無線產品整合測試」為主題總結。 除了精彩的演講分享，現場透過設置四大展示區域讓與會者親身體驗最先進的技術方案。包括無線通訊自動化整合測試方案、智慧工廠協作自動化方案、EMI電磁波自動掃描系統，以及量測儀器新思維的租/買並存方案。透過實際操作與互動，體驗技術應用潛力與創新價值。 本次研討會成功展現筑波科技在無線通訊與智慧協作領域的技術領導地位，更為產業界提供寶貴的交流平台，促進各方對創新技術的理解與合作。未來，筑波科技將持續精進技術與服務，與產業夥伴攜手共創智慧時代的嶄新篇章。
Steps up R&D investment Focuses on precision medicine and intelligent testing sectors HONG KONG, March 25, 2024 /PRNewswire/ -- Yunkang Group Limited ("Yunkang" or the "Group"; Stock Code: 2325), a leading medical operation services provider in China, has announced its annual results for the year ended December 31, 2023 (the "Reporting Period"). In 2023, the Group continued to expand its business network and services across the country, the Group's revenue reached RMB891.5 million. The Group's routine testing business achieved a healthy and steady year-on-year growth of 26.9% during the Reporting Period. Due to enhanced operational and management capabilities and improved cost control, the overall gross profit margin remained stable at 36.5%. The Group further improved its operational and management capabilities and strengthened its cash flow management, resulting in a significant improvement in net cash generated from operating activities as compared with last year. As at December 31, 2023, the Group's cash and cash equivalents amounted to RMB1,244.1 million. The Board of Directors resolved to recommend the payment of a final dividend of HK$0.02 per share for the year ended December 31, 2023. Continuously expanding the business network, improving the testing servicesTo better meet customers' needs, in addition to expanding its business network, the Group increased investment in research & development ("R&D") for new technologies and new products, while launching many competitive testing services and continuing to expand into secondary and tertiary hospitals. As at December 31, 2023, the Group had 12 independent medical laboratories and 416 co-laboratories with leading hospitals, providing over 3,000 test items and over 10 million tests per year, and the Group had established a customer service network covering over 200 cities in 31 provinces and autonomous regions across China. Actively supported the establishment of medical institution alliances and promoted the development of hospitals with in-depth servicesSince the introduction of the new medical reforms, the Group has actively responded to the policy and leveraged its advantages in specialization, standardization and digital intelligence to empower the medical institutions at all levels within the medical institution alliances to enhance their medical diagnostic and collaborative service capabilities and form a distinctive model for the operation and innovation of medical institution alliances. Meanwhile, in the joint collaboration with hospitals, the Group not only provided "3+1" (i.e. tumor, infection, genetics and reproduction + precision medicine) technical system support, but also supported the in-depth service system, including the operation of diagnostic centers under regional medical institution alliances, the introduction of new technologies or new products, construction services for digital specialized clinical disciplines, medical cold chain logistics services, quality control services and supply chain services, so as to empower the development of hospitals with in-depth services. In addition, the Group also rapidly replicated the joint innovation platform model for diagnostic testing. During the Reporting Period, the Group cooperated with Guangdong Provincial People's Hospital to establish the joint innovation platform. Promoted technological innovation and continuously stepping up R&D investmentDuring the Reporting Period, the Group's investment in R&D amounted to RMB55.3 million, which increased as a percentage of operating revenue to 6.2% for the year ended December 31, 2023. As the end of the Reporting Period, the Group was granted a total of 319 patents and intellectual property rights, including approved invention patents, approved utility model patents, software copyright patents, etc. By strengthening cooperation with universities and research institutions, the Group actively carries out the research and development of new technologies, and jointly promotes the research and development of cutting-edge testing technologies and their marketization. During the year, the Group continued to maintain long-term and stable cooperative relationships with the University of Chicago, the University of Toronto, Fudan University, Sun Yat-sen University, the Southern Medical University, Southern University of Science and Technology, Nanchang University and other domestic and overseas universities, providing them with a broad platform and opportunities in joint cultivation, training and internship, scientific research and other areas. The Group attaches great importance to the integration and innovation of research, production and service, actively integrates the resources of domestic and overseas universities, scientific research institutions and high-quality suppliers. In addition, with the assistance of advanced technologies such as digital medical and AI application, the Group helps hospitals build a platform for commercialization of scientific research innovation and achievements. By integrating research, production and service, the Group aim to meet the research and clinical needs of medical institutions, accelerate the industrialization and commercialization of scientific research achievements, and improve the accessibility of high-quality medical resources. Focus on customer service with the application of AI-assisted diagnosis technologyDuring the year, with a focus on the customer-oriented digital intelligent R&D, the Group accelerated the promotion of "Medical Treatment + Digitalization", building and constantly optimizing the remote pathology platform and helping medical institutions at all levels to access the Group's remote pathology consultation network. As at December 31, 2023, Yunkang's remote pathology platform covered 536 medical test items and successfully operated in more than 291 jointly constructed laboratories, comprehensively improved the quality of testing and efficiency of diagnosis, and created a digital pathology consultation system that efficiently empowers medical institutions at all levels. The Group has more than 170 pathologists from home and abroad, with the cumulative number of pathology tests completed via digital pathology exceeding 700,000, helping hospitals to improve the efficiency of their departments by around 45%. Meanwhile, the Group not only actively establishes benchmarking cooperation with medical institutions to build application demonstration sites, but also creates a new model of pathological AI joint initiative to empower medical institutions in improving their diagnostic capabilities and quality. In 2023, by applying AI-assisted cervical liquid-based cytology pathology diagnosis, the Group completed tens of thousands of cervical liquid-based cell sample testing, promoting the continuous advancement of digital pathology technology. Established Precision Medicine Centers and seized industry opportunities ahead of peersPrecision medicine is a personalized approach to healthcare and clinical decision-making for patients based on their unique biological information, clinical symptoms, and physical signs. As increasing number of patients seek personalized medical solutions, precision medicine will continue to gain momentum. Diagnostic testing plays a vital role in advancing precision medicine by enabling doctors to accurately assess patients' symptoms and tailor treatment plans accordingly. With the Group's experience in diagnostic testing and its leading position in the market, it has taken the initiative to capitalize on this industry opportunity as a first mover. As at December 31, 2023, the Group had a total of 12 Precision Medicine Centers constructed by itself or jointly constructed with medical institution alliances, covering three major disease areas: cancer, genetic diseases and infectious diseases. Reducing costs and improving efficiency through lean operationsThe Group has effectively reduced operating costs by optimizing internal management processes and improving operational efficiency, as well as actively establishing long-term and stable cooperative relationships with suppliers to ensure stable supply and cost control. During the Reporting Period, the Group completed the "Robust Project Scheme". By organizing its internal value creation process, the Group set quality standards, established timeliness and cost control points in the process, analyzed the gap between the current situation and the standards, and established rules and mechanisms to avoid disorganization. Actively practiced ESG philosophy with high recognition for corporate governanceDuring the Reporting Period, the Group actively ensured compliance with the requirements of the new regulations of the Stock Exchange, established a sound ESG and climate change management system, actively identified and evaluated important ESG issues, supervised the effective implementation of ESG-related targets and daily implementation, and continuously enhanced the sustainable development management capabilities. In terms of corporate governance, the Group's efforts have been well recognized by the market. The Group won several awards during the Reporting Period, including four awards in the 2022 Vision Awards Annual Report Competition organized by the League of American Communications Professionals, the "ESG Special Recognition Award" in the 2023 Environmental, Social and Governance Awards organized by the Hong Kong Television Broadcasts Limited, and three major awards in the 7th China IR Annual Awards. Future development StrategiesThe Group will adopt active development strategies to achieve its long-term objectives, including optimizing the allocation of medical resources and accelerating industry development. The Group will continue to deepen and promote cooperation with key customers through the mode of school-enterprise cooperation and innovative collaboration between hospitals and diagnostic testing services, focusing on customer demand and enhancing the value of Yunkang. In addition, the Group will continue to increase investment in technological innovation and R&D and implement new product development mechanisms to enhance the competitiveness of the Group's products. Meanwhile, the Group will adhere to digitalized construction and enhance the operational performance of jointly constructed laboratories by deepening the operation and management of jointly constructed laboratories. The Group will increase R&D investment and seek cooperation with industry leaders to further maintain its leading position in the domestic market. Mr. Zhang Yong, Chairman and Executive Director of YunKang Group Limited, said, "Benefiting from favorable national policies supporting the deepening of medical services supply structure reforms and the promotion of compact county medical and healthcare alliances, the medical testing service market has been presented with new opportunities. Looking ahead, the Group will continue to adhere to its business principle of 'in-depth services and lean operations', and its innovation-driven and service-oriented philosophy to actively promote lean management and digital empowerment. It will also follow the direction of national policies and seize development opportunities in the medical testing market to provide better and more competitive diagnostic testing services to the public, contribute to the realization of the 'Healthy China 2030' blueprint, and generate long-term returns for shareholders." Yunkang Group Limited (Stock Code：2325) Yunkang Group is a leading medical operation service provider in China, which started to provide standardized medical diagnostic services to medical institutions at all levels as early as 2008. Leveraging its own professional diagnostic capabilities and the nationwide service network of integrated healthcare systems, Yunkang has gradually grown to become a medical operation service platform. Meanwhile, Yunkang is a medical operation service provider in China offering a full suite of diagnostic testing services which are diagnostic outsourcing services and diagnostic testing services for medical institution alliances. Yunkang provides diagnostic services through on-site diagnostic centers to collaborative hospitals in the integrated healthcare systems in China and assists them in improving their clinical diagnosis capabilities through co-developing diagnostic centers. As of today, Yunkang has successfully provided professional services to 416 medical institution alliances. As of December 31, 2023, the hospitals we collaborated with were located across 31 provinces and municipalities in China. Media InquiriesYunkang Group LtdVenus Zhao General Manager of Hong Kong Office, General Manager of Capital Markets and Corporate CommunicationE-mail: zhaohui@yunkanghealth.comWebsite: www.yunkanghealth.com
Applitools Intelligent Testing Platform is the first to seamlessly combine the power of code-based testing with the simplicity of codeless autonomous testing, making it accessible to all regardless of coding experience SAN MATEO, Calif., Feb. 7, 2024 /PRNewswire/ -- Applitools, the industry leader for AI-powered test automation, today announced Autonomous, the first fully autonomous test automation solution that automatically generates tests on websites and multi-page web applications and uses Natural Language Processing (NLP) to allow developers, test engineers and business users to author automated tests using plain English. Autonomous brings the power of the Applitools Intelligent Testing Platform to everyone, from developers and quality assurance (QA) professionals to digital marketers, to efficiently build, maintain and execute functional and visual tests in minutes across all environments, browsers and devices. Register for this webinar with Applitools' co-founder and CTO Adam Carmi, and DevRel Dave Piacente, to learn more: applitools.info/fae Testing Challenges for Modern Business The ability to deliver new digital products and features into the hands of consumers is now a competitive advantage. According to a report by TCGen, enterprises that reduce their time to market accrue greater revenue over time. As development time continues to speed up, pressure grows for development and testing teams to deliver digital experiences that render accurately all the time. Businesses today face significant challenges in validating the functionality and appearance of their digital assets across multiple screens, browsers and devices, with UI/UX updates required multiple times a week or even per day. Traditional testing tools struggle to match the pace of development, resulting in trade-offs between test coverage, velocity and quality. This often leads to issues such as bugs in production, reduced release confidence, increased costs, slow feedback loops, and delayed timelines, prompting businesses to establish large and costly QA organizations, causing silos and inefficiencies. Introducing Applitools Intelligent Testing Platform Applitools, the leader in AI Powered Automated Testing, is transforming testing with its new Autonomous capabilities. By empowering non-technical (i.e. digital marketers, product experts, etc.) and technical team members (i.e. manual QA testers) to run visual and functional tests easily, Applitools is democratizing testing and driving high-quality, reliable products. Applitools is the only platform that allows combining codeless testing with code-based testing using existing open-source test frameworks. With the Intelligent Testing Platform, engineering and product teams reduce risk, improve delivery velocity, and deliver superior digital experiences that align with consumer expectations and business goals, ushering in a new testing standard. Applitools Autonomous crawls and scans web applications to generate and automatically maintain test cases for each page, while Visual AI validates the entire UI for any functional or visual regressions. These tests can be seamlessly integrated into CI/CD pipelines or scheduled, allowing businesses to monitor critical digital assets effortlessly. With natural language test building and contextual UI testing, teams can author tests with GenAI capabilities and leverage Visual AI to improve coverage and test reliability. This infrastructure supports running at a large scale with speed and stability that exceeds any other product in the market and provides intelligent test infrastructure that self-heals around UI changes and flexible execution options. EVERSANA, a leading provider of global commercial services to the life sciences industry, has been one of the early adopters of Applitools Autonomous. EVERSANA's agency team at EVERSANA INTOUCH has tapped into Applitools' test automation capabilities to accelerate transformation initiatives. "Our testing process transformed when we started using the Applitools Intelligent Testing Platform," said Michael Blake, Senior Vice President, Development & Quality Services at EVERSANA INTOUCH. "Through this technology, we've been able to significantly accelerate all testing and deployments, transforming processes that would take days to just hours, allowing us to deliver faster and better results for clients." With the addition of Autonomous, the Applitools Intelligent Testing Platform stands at the forefront of AI-powered test automation across applications and documents. The platform now includes five powerful solutions that, together, will change the way organizations ensure error-free digital experiences: Autonomous: a game-changing generative test platform for web and multi-page web applications that reduces manual work at every stage of the testing lifecycle. It automatically generates and self-maintains comprehensive, powerful and resilient test suites, and allows using plain English and Visual AI to validate complex scenarios. Preflight: a codeless testing platform for QA professionals building comprehensive, end-to-end tests for web applications of any complexity. Eyes: an AI-powered engine that can integrate into nearly any test framework and language to help validate any interface, from web applications to mobile applications, documents and more. Ultrafast Grid: the next generation of cross browser testing, Ultrafast Grid allows users to perform visual testing across multiple browsers and devices in seconds, to ensure content is visually perfect on every device, screen size, and browser combination. Execution Cloud: the first cloud-based testing platform with built-in self-healing capabilities that enable engineering and testing teams to run existing tests against an AI-powered test infrastructure. By combining the power of Autonomous, Preflight, Eyes, Ultrafast Grid and Execution Cloud, teams can reduce manual work, create and maintain resilient tests using plain English and involve more teams in the QA process. "The Applitools Intelligent Testing Platform is a game-changer as it empowers tech-savvy individuals and non-developers to leverage Autonomous testing to ensure flawless digital experiences," said Alex Berry, CEO of Applitools. "By harnessing Visual AI and Generative AI, we continue to advance UI test automation to streamline testing processes and expedite the delivery of flawless digital experiences. With Autonomous and our Intelligent Testing Platform, we empower individuals from various teams to contribute to the quality of digital experiences. By fostering cross-team collaboration and putting app and digital asset quality control in all hands, bugs are prevented from reaching production so customers can save resources and invest in innovation and mission-critical endeavors." Try the Applitools Intelligent Platform Today: https://applitools.com/ About Applitools Applitools sets the industry standard for AI-powered test automation, infusing AI into every step of the testing lifecycle. Remarkably intuitive, the Applitools Intelligent Testing Platform empowers every team member - from design, development, QA, operations, marketing and product teams – to contribute to quality assurance, regardless of their coding expertise. With Applitools, companies accelerate their testing processes, embrace comprehensive quality checks, and ensure superior product delivery in less time through proactive, continuous testing. Hundreds of the world's top brands – including more than 25% of the Fortune 500 – trust Applitools to reliably ship applications faster to delight millions of users on any device and browser, and across every screen size and operating system. Applitools is headquartered in San Mateo, California, with an R&D center in Tel Aviv, Israel. To learn more, visit applitools.com. Media Contact:Olivia HeelCatapult PRoheel@catapultpr-ir.com
HONG KONG, July 27, 2023 /PRNewswire/ -- CLPS Incorporation (the "Company" or "CLPS") (Nasdaq: CLPS), today announced the launch of its AI-generated content (AIGC) solution. It is a result of CLPS's extensive research in AI and automation with a focus on improving operational efficiency by reducing project and talent delivery costs. Developed by the CLPS Innovation Lab, the Company's research and development center, the AIGC solution has undergone successful internal trial operations, solidifying its effectiveness and reliability. CLPS utilizes intelligent and automated methods to oversee the entire project lifecycle in delivering the AIGC solution. Semantic understanding and logical inference are facilitated using large language model (LLM), while generative AI autonomously produces code that adheres to standards and specifications. The code then undergoes automated testing and optimization via an intelligent testing system. These advancements significantly enhance project execution speed and ensure a higher level of delivery quality. When it comes to talent acquisition, CLPS offers a new matching algorithm and communication mechanism. AIGC performs semantic analysis and keyword extraction on project talent requirements, generating talent skill matching and filtering suggestions. With the support of RPA and big data technologies, qualified talents are quickly assigned to their respective project positions from a vast résumé database, effectively reducing time and talent acquisition costs. As a result, the workload that previously required a team of 120 people in the recruitment center can now be efficiently completed with just 20 people. Ms. Jing Zhao, Senior Vice President of CLPS Innovation Lab, said, "The launch of the AIGC solution signifies a remarkable breakthrough for CLPS in the AI and automation landscape. It is expected to play a critical role in reducing operational costs, enhancing operational efficiency and boosting project success rates for companies. Moving forward, we plan to expand its coverage and gradually extend our services to financial management, customer acquisition, and other domains, offering more comprehensive enhancement solutions for businesses." Mr. Raymond Lin, Chief Executive Officer of CLPS, commented, "In the future, CLPS overseas team will explore ChatGPT's large-scale pre-trained language model, seamlessly integrating big data, machine learning, and RPA, among other cutting-edge technologies with the AIGC solution. This strategic approach aims to significantly enhance the efficiency of project and talent delivery while concurrently reducing costs. CLPS remains dedicated to consistently delivering the most competitive and innovative solutions across diverse industries and corporate clients, empowering them to achieve success amidst a rapidly evolving market." About CLPS Incorporation Headquartered in Hong Kong, CLPS Incorporation (the "Company") (Nasdaq: CLPS) is a global leading information technology ("IT"), consulting and solutions service provider focusing on the banking, insurance and financial sectors. The Company serves as an IT solutions provider to a growing network of clients in the global financial industry, including large financial institutions in the US, Europe, Australia, Southeast Asia and Hong Kong, and their PRC-based IT centers. The Company maintains 19 delivery and/or research & development centers to serve different customers in various geographic locations. Mainland China centers are located in Shanghai, Beijing, Dalian, Tianjin, Xi'an, Chengdu, Guangzhou, Shenzhen, Hangzhou, and Hainan. The remaining nine global centers are located in Hong Kong SAR, USA, Japan, Singapore, Australia, Malaysia, India, the Philippines and Vietnam. For further information regarding the Company, please visit: https://ir.clpsglobal.com/, or follow CLPS on Facebook, Instagram, LinkedIn, Twitter, and YouTube. Forward-Looking Statements Certain of the statements made in this press release are "forward-looking statements" within the meaning and protections of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include statements with respect to the Company's beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions, and future performance. Known and unknown risks, uncertainties and other factors, which may be beyond the Company's control, may cause the actual results and performance of the Company to be materially different from such forward-looking statements. All such statements attributable to us are expressly qualified in their entirety by this cautionary notice, including, without limitation, those risks and uncertainties related to the Company's expectations of the Company's future growth, performance and results of operations, the Company's ability to capitalize on various commercial, M&A, technology and other related opportunities and initiatives, as well as the risks and uncertainties described in the Company's most recently filed SEC reports and filings. Such reports are available upon request from the Company, or from the Securities and Exchange Commission, including through the SEC's Internet website at http://www.sec.gov. We have no obligation and do not undertake to update, revise or correct any of the forward-looking statements after the date hereof, or after the respective dates on which any such statements otherwise are made. Contact: CLPS IncorporationRhon GalichaInvestor Relations Office Phone: +86-182-2192-5378 Email: ir@clpsglobal.com
SINGAPORE, July 24, 2023 /PRNewswire/ -- Singapore-based Motion G, Inc. has closed a new round of funding led by Episteme, Inc., securing an additional US$16 million. By leveraging advancements in machine learning, AIGC, data science and digital twin technologies, the firm aims to revolutionize the engineering process to significantly drive productivity. Through its AI-powered generative engineering platform, Motion G delivers groundbreaking integrated solutions for industry applications including motion control and flexible transport, raising the bar for productivity by accelerating projects from concepts to reality with unparalleled speed and accuracy. The solutions have been applied rapidly in multiple industries. In its pursuit of transforming traditional testing practices, Motion G is also creating an intelligent testing system which will enable engineers to seamlessly combine generative virtual trials with real-time field testing, dramatically increasing overall efficiency. Through these exemplary innovations, Motion G is dedicated to pushing the boundaries of what is possible and engineering a productivity revolution across industries.
Intelligent Testing
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
